come across [20,000/mm:500/mm 3 3 consecutive daily assessments. Platelet engraftment was defined as untransfused platelet counts > 20,000/mm 3 3 consecutive daily assessments. Nonengraftment was defined as failure to reach an ANC > 500/mm 3 3 consecutive daily assessments by Day 90-100. Myeloablation, neutrophil engraftment and platelet engraftment were achieved by all 61 patients. Myeloablation occurred on ASCT Day 5 (range ASCT days -1 to 6) with the median time to myeloablation from dosing of 8 days. The median time to neutrophil engraftment was 12 days (range ASCT days 10 to 16). The median time to platelet engraftment was 13 days (range ASCT days 10 to 28). Palliative Treatment of Patients with Multiple Myeloma A randomized trial compared prednisone plus IV melphalan to prednisone plus oral melphalan in the treatment of multiple myeloma. As discussed below, Overall Response Rates at Week 22 were comparable; however, because of changes in trial design, conclusions as to the relative activity of the 2 formulations after Week 22 are impossible to make. Both arms received oral prednisone starting at 0.8 mg/kg/day with doses tapered over 6 weeks. Melphalan doses in each arm were: Arm 1: Oral melphalan 0.15 mg/kg/day x 7 followed by 0.05 mg/kg/day when WBC began to rise. Arm 2: IV melphalan 16 mg/m 2 q 2 weeks x 4 (over 6 weeks) followed by the same dose every 4 weeks. One hundred seven patients were randomized to the oral melphalan arm and 203 patients to the IV melphalan arm. More patients had a poor-risk classification (58% versus 44%) and high tumor load (51% versus 34%) on the oral arm compared to the IV arm (P] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only D Pregnancy Category Positive evidence of risk N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Spectrum Pharmaceuticals, Inc. Drug Class Alkylating agents Related Drugs alkylating agents carboplatin , cisplatin , cyclophosphamide , oxaliplatin , Cytoxan , Temodar Multiple Myeloma dexamethasone , Decadron , Revlimid , cyclophosphamide , Cytoxan , Adriamycin , doxorubicin , Velcade , Doxil , vincristine , lenalidomide , Pomalyst , thalidomide , bortezomib , carfilzomib , Kyprolis , Ninlaro , melphalan , daratumumab , Thalomid , Dexasone , pomalidomide , ixazomib , carmustine , More... Evomela Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! commonly
photographs Evomela business enterprise
EmoticonEmoticon